A radiation oncology clinician scientist devoted to building an inclusive clinical research program in an integrated academic satellite network in service to the National Cancer Institute

放射肿瘤学临床科学家致力于在为国家癌症研究所服务的综合学术卫星网络中建立包容性临床研究项目

• 批准号: 10561290
• 负责人: Stephen G Chun
• 金额: $ 8.67万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10561290
• 关键词: Address; Area; Artificial Intelligence; Biological Markers; Calendar; Cancer Center; Clinical Research; Clinical Trials; Development; Doctor of Medicine; Educational workshop; Eligibility Determination; Enrollment; Exclusion Criteria; Faculty; Funding; Funding Mechanisms; Institution; Leadership; Location; Malignant Neoplasms; Malignant neoplasm of central nervous system; Minority Enrollment; Mission; National Cancer Institute; Oncology; Patients; Population Heterogeneity; Principal Investigator; Protocols documentation; Radiation; Radiation Oncology; Radiation Therapy Oncology Group; Research; Research Personnel; Role; Scientist; Services; Texas; Underrepresented Minority; Universities; Woman; career; continuing medical education; demographic disparity; ethnic diversity; health care disparity; inclusion criteria; neurocognitive test; oncology trial; participant enrollment; programs; success

Project Summary This project, proposed by clinician scientist Stephen Chun, M.D. at the University of Texas, M.D. Anderson Cancer Center (MDACC) aims to expand the National Cancer Institute (NCI)-sponsored radiation oncology trial program in the Houston Area Location (HAL) integrated academic satellites and support his national leadership efforts with the NCI-sponsored cooperative groups. Since joining the MDACC faculty, Dr. Chun has led the establishment of the HAL radiation clinical trial program and is the Director of Radiation Oncology Clinical Research for the MDACC HALs. Under his leadership, there has been an unprecedented increase (1% in 2016 to 14% in 2021) in the proportion of HAL patients enrolled on radiation clinical trials. With the NCI-sponsored cooperative groups, Dr. Chun currently serves as national Principal Investigator (PI) of a high-profile NRG Oncology analysis, study champion of NRG/Alliance A082002, MDACC institutional PI of NRG-LU005, and has been a top enroller for NRG Oncology-RTOG 1308 that was previously in jeopardy for closure due to poor accrual. To achieve NCI-funded trial objectives in the MDACC HALs, Dr. Chun will spearhead the implementation and expansion of a translational biomarker program, neurocognitive testing capabilities for NCI-sponsored central nervous system (CNS) cancer trials, and the continuing medical education program on clinical research. Dr. Chun is passionate about addressing healthcare disparities and is committed to establish a workflow to track numbers of women and underrepresented minorities enrolled on clinical trials in the HALs, and independently scrutinize patient inclusion and exclusion criteria and factors among to reduce demographic disparities. In order to develop new research capabilities, Dr. Chun will join the leadership of the Protocol in a Day Workshop, which is responsible for developing MDACC investigator-initiated radiation trials, establish the radiation clinical research program at new and planned MDACC facilities, leverage artificial intelligence to capture more patients eligible for trials, and continue to develop concepts with the NCI-sponsored cooperative groups. He will commit a minimum of 20% of his effort (2.4 calendar months) to NCI-sponsored clinical research, and MDACC is committed to support Dr. Chun’s efforts and conduct of NCI-supported clinical trials. The primary objective of his career is to prioritize and expand institutional and NCI-sponsored trials in the MDACC HALs which aligns with this R50 funding mechanism as well as with the broader mission of NCI.

项目摘要 该项目由临床医生斯蒂芬·春（Stephen Chun，M.D。 癌症中心（MDACC）旨在扩大国家癌症研究所（NCI）赞助的辐射肿瘤学试验 休斯顿地区位置（HAL）综合学术卫星的计划并支持他的国家领导 自加入MDACC教职员工以来，NCI赞助的合作团体领导了您 建立HAL辐射临床试验计划和辐射肿瘤临床主任 MDACC HALS的研究。 在2021年的14％中）在接受NCI赞助的HAL患者的建议中 Chun博士目前担任高调NRG的国家首席研究员（PI） 肿瘤分析，NRG/Alliance A082002的学习拥护者，NRG-LU005的MDACC Institute PI，并具有 是NRG肿瘤学-rtog 1308的最高招生者 应计。 和扩展转化生物标志物计划，NCI赞助的神经认知测试能力 中枢神经系统（CNS）癌症试验以及临床研究的凝结医学教育计划。 Chun博士热衷于解决医疗保健差异，并致力于建立工作流程以跟踪 在HALS进行临床试验的妇女和代表性不足的少数族裔的人数不足 仔细检查包容性和排除标准，以及减少人口差异的因素。 为了发展新的研究能力，Chun博士将在日常研讨会中加入协议的领导 负责开发MDACC研究者入侵者引发的辐射试验，建立辐射临床 新的和计划的MDACC设施的研究计划，利用人工智能捕获更多的患者 他会委托。 NCI赞助的临床研究至少有20％的努力（2.4个日历月），而MDACC为 致力于支持Chun博士的主体和NCI支持的临床试验的行为。 职业是在MDACC HALSS中优先级和扩展Intitional和NCI赞助的试验 与NCI更广泛的任务一样，这种R50资金机制也是如此。